Is ZBH a good stock to buy? We came across a bullish thesis on Zimmer Biomet Holdings, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on ZBH. Zimmer Biomet Holdings, Inc.’s share was trading at $87.27 as of June 8th. ZBH’s trailing and forward P/E were 22.62 and 10.46 respectively according to Yahoo Finance.
ldutko/Shutterstock.com
Zimmer Biomet Holdings, Inc. (ZBH) is positioned as a leading player in the global musculoskeletal healthcare market, with dominant share in hip and knee replacements supported by a broad portfolio of orthopedic implants, surgical products, and enabling technologies. The company continues to benefit from favorable long-term industry trends, including aging populations, rising healthcare access, and growing demand for joint reconstruction procedures.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
ZBH has further strengthened its competitive position through increasing surgeon adoption of its cementless implant systems and the ROSA robotic-assisted surgery platform, which is helping improve surgical precision and workflow efficiency while deepening customer relationships. The company is also expanding into faster-growing categories such as upper extremities, foot and ankle, and craniomaxillofacial solutions, broadening its addressable market beyond traditional joint reconstruction.
Its integration of Paragon 28 enhances exposure to the attractive foot and ankle segment, while development of Monogram’s mBos semi-autonomous robotic technology could further reinforce its leadership in next-generation orthopedic procedures. Although concerns have emerged around GLP-1 weight loss drugs potentially reducing future joint replacement demand, Zimmer believes structural demographic trends and increased procedure accessibility should continue driving long-term growth.
Financially, the company generates strong cash flow that supports disciplined capital allocation, acquisitions, and ongoing share repurchases. Despite its market leadership, recurring revenue profile, and expanding robotics ecosystem, ZBH trades near 12 times earnings, materially below its historical valuation closer to 20 times earnings, suggesting meaningful upside potential as execution improves and investors increasingly recognize the durability of its long-term growth trajectory.
Previously, we covered a bullish thesis on Zimmer Biomet Holdings, Inc. (ZBH) by QuestforYield in March 2025, which highlighted the company’s leadership in orthopedic implants, robotics adoption, and strong free cash flow generation. ZBH’s stock price has depreciated by approximately 16.07% since our coverage. @MoneyShow shares a similar view but emphasizes on expansion into higher-growth orthopedic categories and next-generation robotic technologies.
Zimmer Biomet Holdings, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 36 hedge fund portfolios held ZBH at the end of the first quarter which was 41 in the previous quarter. While we acknowledge the risk and potential of ZBH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ZBH and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
